Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics

Atara Biotherapeutics has a market cap or net worth of CHF75.16M. The enterprise value is CHF214.12.

Atara Biotherapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Atara Biotherapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is 222.66%.

The current PE Ratio of Atara Biotherapeutics is ―. Atara Biotherapeutics’s PEG ratio is -0.06.

In the last 12 months, Atara Biotherapeutics had revenue of 120.77M and earned 32.69M in profits. Earnings per share was 2.61.

In the last 12 months, operating cash flow was -21.89M and capital expenditures 0.00, giving a free cash flow of -21.89M billion.

Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Atara Biotherapeutics upcoming earnings date is Oct 29, 2026, TBA (Confirmed).

Atara Biotherapeutics as a current ratio of 0.82, with Debt / Equity ratio of -26.70%

In the past 12 months, Atara Biotherapeutics has paid 31.00K in taxes.

Atara Biotherapeutics EV to EBITDA ratio is 7.02, with an EV/FCF ratio of -5.32.

Atara Biotherapeutics has CHF9.87M in cash and marketable securities with CHF9.88M in debt, giving a net cash position of -CHF6.00K billion.

Gross margin is 91.38%, with operating margin of 29.69%, and net profit margin of 27.07%.

The average price target for Atara Biotherapeutics is CHF12.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy